Non-interventional Cohort Study of Patients Treated With Lisocabtagene Maraleucel (Liso-cel) for Relapsed/Refractory Mantle Cell Lymphoma in the Post-Marketing Setting
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Summary
The purpose of this study is to understand the long-term safety and effectiveness of lisocabtagene maraleucel (liso-cel) for the treatment of Mantle Cell Lymphoma (MCL).
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: • Participants must have been treated in the postmarketing setting with at least 1 infusion of lisocabtagene maraleucel (Liso-cel) used for the treatment of Mantle Cell Lymphoma (MCL) according to the FDA-approved indication and dose range (ie, per the US Prescribing Information) and with a product meeting the specifications for commercial release approved in the USA Exclusion Criteria: * Participants known to be participating in investigational studies at the time of liso-cel infusion. * Participants treated with non-conforming CAR T-cell product.
Interventions
- BiologicalLisocabtagene maraleucel
According to US Prescribing Information
Location
- Center for International Blood and Marrow Transplant Research (CIBMTR)Milwaukee, Wisconsin